An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
- PMID: 9343211
- PMCID: PMC192317
- DOI: 10.1128/JVI.71.11.8531-8541.1997
An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
Abstract
Six female rhesus macaques were immunized orally and intranasally at 0 weeks and intratracheally at 12 weeks with an adenovirus type 5 host range mutant (Ad5hr)-simian immunodeficiency virus SIVsm env recombinant and at 24 and 36 weeks with native SIVmac251 gp120 in Syntex adjuvant. Four macaques received the Ad5hr vector and adjuvant alone; two additional controls were naive. In vivo replication of the Ad5hr wild-type and recombinant vectors occurred with detection of Ad5 DNA in stool samples and/or nasal secretions in all macaques and increases in Ad5 neutralizing antibody in 9 of 10 macaques following Ad administrations. SIV-specific neutralizing antibodies appeared after the second recombinant immunization and rose to titers > 10,000 following the second subunit boost. Immunoglobulin G (IgG) and IgA antibodies able to bind gp120 developed in nasal and rectal secretions, and SIV-specific IgGs were also observed in vaginal secretions and saliva. T-cell proliferative responses to SIV gp140 and T-helper epitopes were sporadically detected in all immunized macaques. Following vaginal challenge with SIVmac251, transient or persistent infection resulted in both immunized and control monkeys. The mean viral burden in persistently infected immunized macaques was significantly decreased in the primary infection period compared to that of control macaques. These results establish in vivo use of the Ad5hr vector, which overcomes the host range restriction of human Ads for rhesus macaques, thereby providing a new model for evaluation of Ad-based vaccines. In addition, they show that a vaccine regimen using the Ad5hr-SIV env recombinant and gp120 subunit induces strong humoral, cellular, and mucosal immunity in rhesus macaques. The reduced viral burden achieved solely with an env-based vaccine supports further development of Ad-based vaccines comprising additional viral components for immune therapy and AIDS vaccine development.
Similar articles
-
Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.J Virol. 1999 Sep;73(9):7430-40. doi: 10.1128/JVI.73.9.7430-7440.1999. J Virol. 1999. PMID: 10438833 Free PMC article.
-
Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.J Virol. 2003 Aug;77(15):8354-65. doi: 10.1128/jvi.77.15.8354-8365.2003. J Virol. 2003. PMID: 12857905 Free PMC article.
-
A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.J Immunol. 2003 Apr 15;170(8):4281-9. doi: 10.4049/jimmunol.170.8.4281. J Immunol. 2003. PMID: 12682263
-
Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6.J Intern Med. 2009 Jan;265(1):67-77. doi: 10.1111/j.1365-2796.2008.02051.x. J Intern Med. 2009. PMID: 19093961 Free PMC article. Review.
-
SIV infected rhesus macaques: an AIDS model for immunoprevention and immunotherapy.Adv Exp Med Biol. 1989;251:279-93. doi: 10.1007/978-1-4757-2046-4_26. Adv Exp Med Biol. 1989. PMID: 2558527 Review.
Cited by
-
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.J Virol. 1999 Jan;73(1):618-30. doi: 10.1128/JVI.73.1.618-630.1999. J Virol. 1999. PMID: 9847367 Free PMC article.
-
Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.J Virol. 1999 Sep;73(9):7430-40. doi: 10.1128/JVI.73.9.7430-7440.1999. J Virol. 1999. PMID: 10438833 Free PMC article.
-
Oral vaccination as a potential strategy to manage chronic wasting disease in wild cervid populations.Front Immunol. 2023 Apr 14;14:1156451. doi: 10.3389/fimmu.2023.1156451. eCollection 2023. Front Immunol. 2023. PMID: 37122761 Free PMC article. Review.
-
TFH Cells Induced by Vaccination and Following SIV Challenge Support Env-Specific Humoral Immunity in the Rectal-Genital Tract and Circulation of Female Rhesus Macaques.Front Immunol. 2021 Jan 28;11:608003. doi: 10.3389/fimmu.2020.608003. eCollection 2020. Front Immunol. 2021. PMID: 33584682 Free PMC article.
-
Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope.Vaccines (Basel). 2020 Feb 2;8(1):64. doi: 10.3390/vaccines8010064. Vaccines (Basel). 2020. PMID: 32024265 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous